Ken Griffin Entera Bio Ltd. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.48 - $2.14 $3,848 - $5,564	2,600 New	2,600 $4,000
Q1 2024 May 15, 2024	SELL	$0.64 - $1.72 $4,608 - $12,384	-7,200 Reduced 64.86%	3,900 $6,000
Q4 2023 Feb 14, 2024	BUY	$0.55 - $0.74 $220 - $296	400 Added 3.74%	11,100 $6,000
Q3 2023 Nov 14, 2023	SELL	$0.6 - $0.88 $1,200 - $1,760	-2,000 Reduced 15.75%	10,700 $7,000
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.01 $2,516 - $3,737	3,700 Added 41.11%	12,700 $10,000
Q1 2023 May 15, 2023	SELL	$0.83 - $1.44 $74,202 - $128,736	-89,400 Reduced 90.85%	9,000 $10,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.05 $550 - $1,155	-1,100 Reduced 1.11%	98,400 $71,000
Q3 2022 Nov 14, 2022	BUY	$0.07 - $1.98 $14 - $396	200 Added 0.2%	99,500 $103,000

5.34M

2.6K

100

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $49.8M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.